All In Biotech

Drug Trial Radar · NCT07614152

The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Inpegsomatropin Injection Versus Givopegsomatropin Solution Injection in the Treatment of Short Stature in Children With Turner Syndrome.

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Jul 5, 2026

Primary completion

Mar 30, 2028

Study completion Feb 28, 2030

Sponsor

Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 2 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, positive-controlled phase III confirmatory clinical study. A total of 84 children with short stature due to Turner Syndrome (TS) are planned to be enrolled. Stratified by age and karyotype, subjects will be randomized at a 1:1 ratio to either the test group or the positive control group with continuous treatment for 52 weeks. The study aims to compare the efficacy and safety of Inpegsomatropin-Injection versus Givopegsomatropin Solution Injection in children with TS-related short stature, so as to provide evidence for the new indication application of the investigational drug.

Conditions

  • Turner Syndrome

Interventions

  • Inpegsomatropin-InjectionDrug

    Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly, for 52 weeks.

  • Givopegsomatropin Solution InjectionDrug

    Givopegsomatropin Solution Injection, 200 μg/kg/week, s.c., once weekly, for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Growth velocity (HV, cm/year).Time frame: Week 52

Locations

51 sites in 1 country. Site status is shown where the registry gives one.

  • Anyang Maternal and Child Health Hospital

    Anyang, China · Recruiting

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Capital Institute of Pediatrics, Capital Medical University

    Beijing, China · Recruiting

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Peking University First Hospital

    Beijing, China · Recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, China · Recruiting

  • Chengdu Women's and Children's Central Hospital

    Chengdu, China · Recruiting

  • Children's Hospital of Chongqing Medical University

    Chongqing, China · Recruiting

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, China · Recruiting

  • Guangdong Provincial Maternal and Child Health Hospital

    Guangzhou, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Zhejiang Provincial Hospital of Traditional Chinese Medicine

    Hangzhou, China · Recruiting

  • The First Affiliated Hospital of Hebei North University

    Hebei, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Henan, China · Recruiting

  • Huzhou Central Hospital

    Huzhou, China · Recruiting

  • Jiangxi Provincial Children's Hospital

    Jiangxi, China · Recruiting

  • The First Hospital of Jilin University

    Jilin City, China · Recruiting

  • Shandong Provincial Hospital

    Jinan, China · Recruiting

  • Affiliated Hospital of Jining Medical University

    Jining, China · Recruiting

  • Kunming Children's Hospital

    Kunming, China · Recruiting

  • Gansu Provincial People's Hospital

    Lanzhou, China · Recruiting

  • The Second Affiliated Hospital of Guangxi Medical University

    Nanning, China · Recruiting

  • Pingxiang People's Hospital

    Pingxiang, China · Recruiting

  • Qilu Hospital of Shandong University

    Qilu, China · Recruiting

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Shanghai Children's Hospital

    Shanghai, China · Recruiting

  • Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

    Shanxi, China · Recruiting

  • Shaoxing People's Hospital

    Shaoxing, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, China · Recruiting

  • Shenzhen Children's Hospital

    Shenzhen, China · Recruiting

  • West China Second University Hospital, Sichuan University

    Sichuan, China · Recruiting

  • Children's Hospital of Soochow University

    Suzhou, China · Recruiting

  • Taizhou First People's Hospital

    Taizhou, China · Recruiting

  • Taizhou People's Hospital

    Taizhou, China · Recruiting

  • Tangshan Maternal and Child Health Hospital

    Tangshan, China · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.